by Maria Zannes | Mar 23, 2023 | Press Releases
SAN ANTONIO, Texas (March 24, 2023) – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a...
by Dale Harrison | Feb 13, 2023 | Press Releases
Company enlists Havas Health & You, Trinity Life Sciences to help build CyPath® Lungbrand SAN ANTONIO, TX – Feb. 13, 2023 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced its commercialization team, including the addition of Julie Anne...
by Dale Harrison | Jan 24, 2023 | Press Releases
Noninvasive Test Developed Using Machine Learning Detects Early-Stage Lung Cancer with High Sensitivity and Specificity SAN ANTONIO, TX – Jan 24, 2023 – – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced publication of “Detection of early-stage...
by Dale Harrison | Jan 4, 2023 | Press Releases
SAN ANTONIO, TX – Jan 4, 2023 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced today that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent application titled “Porphyrin Compounds and Compositions Useful for...
by Dale Harrison | Dec 15, 2022 | Press Releases
SAN ANTONIO, TX – Dec. 15, 2022 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as targeted cancer treatment, today announced that...
by Dale Harrison | Dec 1, 2022 | Press Releases
bioAffinity reports on a potential therapeutic approach that kills cancer cells without harm to normal cells SAN ANTONIO, TX – Dec. 1, 2022 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of...
